Protagonist Therapeutics (NASDAQ: PTGX) CEO sells shares for taxes

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported a sale of company common stock in a Form 4 filing. On January 20, 2026, he sold 34,438 shares of Protagonist Therapeutics common stock at a price of $82.48 per share, reported as a direct ownership transaction.

According to the footnote, the sale was made to cover tax withholding obligations incurred when restricted stock units settled, meaning it was tied to an equity award rather than an open-market discretionary sale of his broader holdings. After this transaction, Patel directly beneficially owned 580,505 shares of Protagonist Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATEL DINESH V PH D

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CA 94560-1160

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S		34,438(1)	D	$82.48	580,505	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units.

	/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Protagonist Therapeutics (PTGX) report for its CEO?

The Form 4 shows that Dinesh V. Patel, President and CEO of Protagonist Therapeutics, reported a sale of 34,438 shares of the company’s common stock on January 20, 2026.

At what price did the PTGX CEO sell shares in the latest Form 4?

The shares of Protagonist Therapeutics common stock were reported sold at a price of $82.48 per share in the January 20, 2026 transaction.

Why did Dinesh V. Patel sell Protagonist Therapeutics (PTGX) shares?

The footnote explains that the sale of 34,438 shares was made to cover tax withholding obligations incurred upon the settlement of restricted stock units.

How many Protagonist Therapeutics shares does the CEO own after this transaction?

Following the reported sale, Dinesh V. Patel beneficially owned 580,505 shares of Protagonist Therapeutics common stock, held as direct ownership.

What is Dinesh V. Patel’s role and relationship to Protagonist Therapeutics (PTGX)?

Dinesh V. Patel is reported as a Director and as an Officer of Protagonist Therapeutics, serving as President and CEO in the Form 4 filing.

Was the Protagonist Therapeutics CEO’s share sale direct or indirect ownership?

The Form 4 lists the 34,438-share sale and the remaining 580,505 shares as held under direct (D) ownership, with no separate indirect ownership entity noted.